Genetic basis of MDS

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Luca Malcovti discusses the genetic basis of myelodysplastic syndromes (MDS).Ea... Author: imedex Added: 10/30/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

Owing to poor prognosis and limited therapeutic modalities, treatment of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) has long been a challenge for researchers [1,2]. In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has provided a potential curative therapy for patients with MDS and MDS/MPN. However, relapse, treatment-related death, and non-relapse mortality (NRM) – which are often related to graft-versus-host disease (GVHD)—remain major obstacles to universally successful transplantation.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
AbstractTriple-negative primary myelofibrosis (TN-PMF) and other myeloid neoplasms with associated bone marrow fibrosis such as the myelodysplastic syndromes (MDS-F) or the myelodysplastic/myeloproliferative neoplasms (MDS/MPN-F) are rare entities, often difficult to distinguish from each other. Thirty-four patients previously diagnosed with TN-PMF (n = 14), MDS-F (n = 18), or MDS/MPN-F (n = 2) were included in the present study. After central revision of the bone marrow histology, diagnoses according to the 2016-WHO classification were TN-PMF (n = 6), MDS-F (n&thinsp...
Source: Annals of Hematology - Category: Hematology Source Type: research
Myelodysplastic syndromes (MDS) are a collection of heterogeneous clonal stem cell disorders that lead to ineffective haematopoiesis and multi-lineage cytopenia. Mutations of SRSF2, a spliceosome component, are found in high-risk MDS (12-15%) and chronic myelomonocytic leukaemia (CMML; 40-50%)- an aggressive myeloproliferative neoplasm (MPN). In patients, SRSF2P95H mutation frequently co-occurs with mutations in other pathways, such as DNA methylation, chromatin modification and transcription. In CMML, co-occurrence of SRSF2 and TET2 mutation is highly prevalent (50-60%) and confers a worse overall survival (OS).
Source: Experimental Hematology - Category: Hematology Authors: Tags: 3155 Source Type: research
CONCLUSIONS: Morphological examination remains the standard for MDS diagnosis. Considering the low incidence of genetically proven ICUS (20.2-27.5%), the low sensitivity of ELN MDS indexes for ICUS is considered a valuable alternative. PMID: 31330512 [PubMed - as supplied by publisher]
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
Several prognostic scoring systems have been developed to assess prognosis in myelodysplastic syndrome (MDS). However, currently there are no systems that list gender as a prognostic factor. We queried a National Cancer Institute database to investigate the prognostic influence of gender on the survival of patients with MDS. We first identified 34,681 qualified patients diagnosed with MDS from 2001-2014 in the Surveillance, Epidemiology, and End Results (SEER) database, and then analyzed the characteristics of these patients using chi-squared tests. The Kaplan-Meier method and the multivariate Cox regression model were use...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Allogeneic hematopoietic cell transplantation (HCT) is the most potent postremission therapy in AML [1, 2], and is widely used in younger patients with intermediate or adverse risk cytogenetics [3]. Transplant decisions are mainly based on the cytogenetic and molecular risk group, age, comorbidity, response to therapy and on the availability of a suitable donor [4]. AML is in more than one fourth of all cases secondary (s-AML), arising after previous chemo- and/or radiotherapy, i.e., therapy-related (t-AML), or developing after an antecedent myeloid disease (AHD-AML), such as myelodysplastic syndromes (MDS) or myeloprolife...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic cell transplantation (HCT) is the most potent postremission therapy in patients with acute myelogenous leukemia (AML) [1,2], and is widely used in younger patients with intermediate-risk or adverse-risk cytogenetics [3]. Transplantation decisions are based mainly on cytogenetic and molecular risk group, age, comorbidity, response to therapy, and the availability of a suitable donor [4]. AML is secondary (s-AML) in more than 25% of all cases, arising after previous chemotherapy and/or radiotherapy (i.e., therapy-related [t-AML]) or developing after an antecedent myeloid disease (AHD-AML), such as my...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 25 May 2019Source: Leukemia Research ReportsAuthor(s): Jihane Belkhair, Abderahim Raissi, Hicham Elyahyaoui, Mustapha Ait Ameur, Mohamed ChakourAbstractAtypical chronic myeloid leukemia (aCML), BCR-ABL1 negative is a rare myelodysplastic syndrome /myeloproliferative neoplasm for which no current standard of care exists. The blood smear of patients with aCML showed prominent immature granulocytosis, and granulocytic dysplasia. We admitted a 58-year-old man with splenomegaly, hyperleukocytosis, anemia, and thrombocytopenia; then cytology, cytogenetic and molecular biology analysis of bone m...
Source: Leukemia Research Reports - Category: Hematology Source Type: research
In this article we provide a practical and comprehensive review of myeloid neoplasms with overlapping myelodysplastic (MDS) and myeloproliferative (MPN) features, with emphasis on recent updates in classification, particularly the utility of morphologic, cytogenetic, and molecular findings in better defining and classifying these disease entities. We provide the reader with a summary of the most recent developments and updates that have helped further our understanding of the genomic landscape, clinicopathologic features, and prognostic elements of myeloid neoplasms with MDS/MPN features.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
CONCLUSION: Automated BM counts on hematology analyzers contributed to the formulation of a SS for the screening discrimination between reactive and MDS BM fluids, which seems to be applicable and informative, regardless of the analyzer used. PMID: 31102331 [PubMed - as supplied by publisher]
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Tags: Int J Lab Hematol Source Type: research
More News: Cancer & Oncology | Genetics | Myelodysplastic Syndrome | Myeloproliferative Disorders